1. Most Discussed
  2. Gainers & Losers
ANP 2.3¢

genasense implications

  1. OrangeJuice

    140 Posts.

    Genta Inc will hold an open meeting for investors and analysts in New York on Wednesday (NY Time), at which it will present an update on results of the
    Phase 3 Randomised Clinical Trial of Genasense(TM) (oblimersen sodium).

    PARIS, Sept 8 (Reuters) - Franco-German drugmaker Aventis (AVEP.PA) said on Monday it expected to decide in coming weeks whether to apply this year
    for U.S. marketing approval for cancer drug Genasense, which it is developing with Genta Inc.

    "We anticipate in a matter of weeks to be in a position to determine whether we can file this year for one of the three lead indications," Aventis Vice President for Drug Innovation Frank Douglas said during a conference call after the company said it had bought rights to another experimental cancer drug.

    Will keep an eye out for this one.

Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.


Thank you for visiting HotCopper

We have detected that you are running ad blocking software.

HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.